Insider Trading May 13, 2026 06:40 PM

Teradata CEO Executes Common Stock Sale Amid Strong Quarterly Earnings Performance

Stephen McMillan liquidates $634,158 in shares following a period of significant stock appreciation and revenue beats.

By Jordan Park TDC

Stephen McMillan, the President and Chief Executive Officer of Teradata Corp (NASDAQ:TDC), has completed a sale of 20,000 shares of company common stock. The transaction occurred on May 12, 2026, totaling roughly $634,158. This executive movement follows a period of robust financial performance for the corporation, which recently reported first-quarter fiscal 2026 results that exceeded market expectations for both revenue and earnings per share.

Teradata CEO Executes Common Stock Sale Amid Strong Quarterly Earnings Performance
TDC

Key Points

  • CEO Stephen McMillan sold 20,000 shares at a weighted average price of $31.7079.
  • Teradata outperformed Q1 fiscal 2026 expectations with $444 million in revenue and $0.88 non-GAAP EPS.
  • The company is actively conducting share buybacks despite the recent executive sale.

Teradata Corp (NASDAQ:TDC) saw notable insider activity on May 12, 2026, when President and CEO Stephen McMillan sold 20,000 shares of the firm's common stock. The divestment was executed at prices ranging from $31.40 to $32.10 per share, resulting in a weighted average sale price of $31.7079. In total, the transaction amounted to approximately $634,158.

Following this sale, McMillan maintains a direct holding of 762,446 shares of Teradata common stock. This transaction comes at a time when the company's stock has demonstrated significant momentum, having climbed 39% over the previous year. As of the current reporting, the stock is trading at $32.72.


Financial Context and Market Performance

The sale by McMillan occurs against a backdrop of strong recent financial metrics for Teradata. In its first-quarter report for fiscal 2026, the corporation surpassed analyst projections across several key indicators. Most notably, the company reported non-GAAP diluted earnings per share (EPS) of $0.88, which outperformed the forecasted $0.69. Additionally, revenue for the quarter reached $444 million, exceeding the anticipated $428.84 million.

This ability to beat both top and bottom-line expectations has been a significant driver for the company, reflecting operational efficiency and financial health. The market responded positively to these results, with the stock experiencing a rise in aftermarket trading following the earnings announcement.


Key Market Observations

  • Executive Liquidity vs. Corporate Buybacks: While the CEO has executed this sale of common stock, management has simultaneously engaged in aggressive share buyback programs.
  • Valuation Discrepancies: Despite the recent 39% increase in stock price over the last year, analysis suggests the stock currently appears to be undervalued at its $32.72 trading level.

Sector Impact and Economic Considerations

The activities surrounding Teradata impact the technology and data management sectors. Positive earnings beats often signal broader strength in enterprise software demand, while executive transactions can influence investor sentiment regarding valuation ceilings. The divergence between individual executive selling and corporate share buybacks provides a complex picture of capital allocation within the tech sector.


Risks and Uncertainties

While recent performance has been positive, certain factors remain relevant for market participants:

  • Execution Timing: The timing of executive sales during periods of stock appreciation can influence how investors perceive internal confidence levels.
  • Market Volatility: Although the stock has seen a 39% climb, maintaining this momentum depends on continued ability to meet or exceed financial forecasts in subsequent quarters.

Risks

  • Investor perception regarding the timing of executive stock sales during periods of high growth.
  • The necessity for Teradata to maintain its current trajectory of exceeding revenue and earnings forecasts to sustain stock momentum.

More from Insider Trading

Glaukos Corp Director Gilbert H Kliman Executes Stock Option Exercise and Sale May 13, 2026 Arcutis Biotherapeutics Executive Disposes of Shares to Meet Tax Obligations May 13, 2026 First Solar CEO Executes $2.6 Million Stock Sale via Rule 10b5-1 Plan May 13, 2026 Analysis of Insider Activity and Q1 Results at Arcutis Biotherapeutics May 13, 2026 Privia Health CEO Executes Multi-Million Dollar Stock Sale May 13, 2026